Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

sus temsirolimus in relapsed or refractory  MCL patients, RAY (MCL3001). This trial is a randomized, multi-center, open-label trial of ibrutinib as a mono-therapy versus temsirolimus in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen. The primary endpoint of the study is progression free survival when compared to temsirolimus. This global study, conducted by Janssen outside the US, is open and Janssen plans to enroll 280 patients.
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with newly diagnosed MCL, SHINE (MCL3002). This trial is a randomized, multi-center, double-blinded, placebo-controlled trial of ibrutinib plus bendamustine and rituximab versus placebo plus bendamustine and rituximab in subjects with newly diagnosed MCL. The primary endpoint of the study is progression free survival when compared to bendamustine and rituximab. Janssen plans to enroll 520 patients in this study.
  • Phase II study of ibrutinib in patients with mantle cell lymphoma who progress after bortezomib therapy, SPARK (MCL2001). This is a single-arm, multi-center trial of ibrutinib as a monotherapy in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. The primary endpoint of the study is overall response rate. This global study, conducted by Janssen, is open and Janssen plans to enroll 110 patients worldwide.
  • Phase II study of ibrutinib in patients with mantle cell lymphoma who progress after bortezomib therapy, SPARK (MCL2001). This is a single-arm, multi-center trial of ibrutinib as a monotherapy in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. The primary endpoint of the study is overall response rate. This global study, conducted by Janssen,
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
    (Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
    (Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... the promotion of Nick Maroulis, Pharm.D. to the newly ... , In this position, Dr. Maroulis will continue ... the directors of our multi-site pharmacies as the company ... and during that time he has served in many ...
    (Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fhh9rj/technology ... "Technology Innovations in Smart Fabrics (Technical Insights)" ... http://photos.prnewswire.com/prnh/20130307/600769 The Research Service ... detailed assessment on technological advancements and market for ... 1. The Smart Fabrics market is expected ...
    Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Technology Innovations in Smart Fabrics (Technical Insights) 2
    ... Wash., Dec. 16 The Australian Patent Office has,issued ... third international,patent, from many patents pending, that the technology ... ingredients like probiotic,organisms from stomach acid on their way ... Steve Moger, President and CEO of Nutraceutix comments: ...
    ... Dec. 16 Epeius Biotechnologies,Corporation, a leader ... additional European patents for the platform targeting ... delivery to primary cancers and,metastatic lesions that ... of clinical benefit and single-agent-efficacy, as well ...
    ... (NYSE Alternext US: CXM) and its operating unit InnerCool ... in a study of Hypothermic Radical Prostatectomy being ... Irvine . The patient was cooled with InnerCool,s ... localized cooling during robotic-assisted prostatectomy surgery. , ...
    Cached Biology Technology:Probiotic Delivery Technology Awarded Third International Patent 2Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate 2Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study 2Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study 3Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study 4Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study 5Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study 6Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study 7Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study 8
    (Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
    (Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
    (Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
    Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
    ... Florida State University oceanography professor Allan Clarke grew up ... the ocean, the beach and the warmth of thesun. Little ... would one day lead him to become an international expert ... a symbol of the professional esteem with which he is ...
    ... a University of Oregon plant biologist suggests, people may want to ... effort to curb the spread of an invasive grass that is ... Brachypodium sylvaticum ), a native of Europe and Asia, which likely ... near Corvallis and Eugene. This grass likely was brought in, along ...
    ... drug development projects for rare and neglected diseases that ... dysfunction disorder, a virus that affects the central nervous ... of muscular dystrophy and a rare lung disease. The ... of Health,s Therapeutics for Rare and Neglected Diseases (TRND) ...
    Cached Biology News:FSU professor wins major meteorology award for research on El Nino 2FSU professor wins major meteorology award for research on El Nino 3Invasive false brome grass is spreading, but Oregon's insects are biting 2Invasive false brome grass is spreading, but Oregon's insects are biting 3NIH TRND program announces next round of drug development projects 2NIH TRND program announces next round of drug development projects 3NIH TRND program announces next round of drug development projects 4NIH TRND program announces next round of drug development projects 5
    Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
    ... miRCURY LNA technology enables sensitive and specific ... hybridisation. miRCURY LNA in situ detection probes ... the specific and sensitive detection of miRNAs. ... possible in whole mounts, thin sections, single ...
    ... Roches RTS AviTag E. coli Biotinylation Kit, ... 100 and 500 E. coli expression kits. (Cat. ... 335 461). This kit provides vectors for the ... peptide sequence. The expressed protein can be enzymatically ...
    ... The EZ DNA Methylation Kit uses a ... for DNA methylation analysis. The kit is ... takes place between cytosine and sodium bisulfite ... EZ DNA Methylation Kits innovative in-column desulphonation ...
    Biology Products: